MARKET

TLSA

TLSA

TIZIANA LIFE SCIENCES PLC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.83
+0.83
+11.86%
After Hours: 7.84 +0.01 +0.13% 19:14 07/10 EDT
OPEN
6.95
PREV CLOSE
7.00
HIGH
8.00
LOW
6.92
VOLUME
207.15K
TURNOVER
--
52 WEEK HIGH
8.56
52 WEEK LOW
1.540
MARKET CAP
260.60M
P/E (TTM)
-11.0422
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TLSA stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.

EPS

TLSA News

More
Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report
NEW YORK and LONDON, July 10, 2020 -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing.
GlobeNewswire · 2d ago
Tiziana Life Sciences Plans To Effect Demerger Of Stemprinter From Group Are Continuing To Be Progressed
-Reuters
Reuters · 07/01 10:13
Company News for Jun 30, 2020
Zacks · 06/30 14:35
NKLA, COTY among premarket gainers
Seeking Alpha - Article · 06/29 12:24
Tiziana Life inks deal for manufacturing of TZLS-501 for COVID-19 patients
Seeking Alpha - Article · 06/29 09:49
Tiziana Life Sciences Announces Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody for Clinical Studies in Patients with COVID-19
NEW YORK and LONDON, June 29, 2020 -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing.
GlobeNewswire · 06/29 07:12
The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs
Benzinga · 06/19 12:41
WKHS, CDEV among premarket gainers
Seeking Alpha - Article · 06/19 12:24

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About TLSA

Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its lead product candidates include Milciclib (TZLS-201) and Foralumab (TZLS-401). Its products also include Anti IK-6r (TZLS-501) and StemPrintER. The Company is focused on its lead compound, Milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division, as well as a number of other protein kinases. Milciclib has completed Phase IIa trials as a monotherapy for the treatment for thymic carcinoma and hepatocellular carcinoma (HCC). The Company's Foralumab is a fully human engineered anti-human cluster of differentiation 3 (CD3) antibody. Foralumab has completed Phase II trial and has potential application in a wide range of autoimmune and inflammatory diseases.
More

Webull offers kinds of Tiziana Life Sciences PLC stock information, including NASDAQ:TLSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLSA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TLSA stock methods without spending real money on the virtual paper trading platform.